Prostate Cancer Awareness: Not Just a Month Prostate cancer awareness isn’t just about blue ribbons in September. As I’ve often said, “Cancer doesn’t take a holiday or a weekend.” Prostate cancer ...

The treatment landscape for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer has expanded significantly, with 3 FDA-approved bladder-sparing therapies now available: pembrolizumab, ...

Key Takeaways Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab ...

The Novel Tracer 89Zr-TLX250 Main Discussion Topics: 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX). CAIX is an enzyme expressed on the surface of most clear cell renal cell ...

Bedke explained, “I think the important message is that we have no specific subgroup which will have a more pronounced benefit of EV+P if compared to the platinum-based chemotherapy. Selecting ...

In the phase 2 COMRADE trial (NCT03317392), reduced-dose olaparib (Lynparza) combined with radium-223 (Ra-223, Xofigo) significantly improved radiographic progression-free survival (rPFS) over Ra-223 ...

The concept of BCG-unresponsive non–muscle-invasive bladder cancer has evolved significantly since its introduction in 2015. This designation is crucial for identifying patients who have received an ...

Recent data show that the use of minimally invasive surgical therapies (MISTs) for the management of benign prostatic hyperplasia (BPH) is increasing among men aged 50 to 65. 1 Overall, MIST ...

The cornerstone for first-line treatment in metastatic prostate cancer is androgen deprivation therapy (ADT), although there are several other options that can be used to personalize treatment to the ...

Clinical Implications for Patient Care Key Themes: Study findings directly inform the treatment of Black men with prostate cancer. Results confirm drug efficacy in this specific population. Data ...

Panelists discuss emerging data comparing bladder-sparing therapies to radical cystectomy in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting the nuanced trade-offs in ...

Physician Summary: Reflections on Progress and Looking Ahead in NMIBC – AUA 2025 As we reflect on the progress made in the treatment of non–muscle-invasive bladder cancer (NMIBC) leading up to AUA ...